Best Halozyme Developments: ENHANZE Deals, HyperCon, and $1B Royalty Guidance

Shoppers of biotech news are watching Halozyme after its annual meeting, where CEO Helen Torley showcased 2025 momentum, two new directors and a roadmap aimed at long-term revenue growth , including ENHANZE deals, acquisitions for concentrated biologics and guidance that pushes royalty revenue to $1 billion in 2026.

Essential Takeaways

• Shareholder approvals: Two Class I directors elected, advisory say-on-pay passed, and Ernst & Young ratified as auditor.
• Platform momentum: ENHANZE now supports 10 globally approved products and added three new agreements in 2025.
• Acquisitions broaden scope: HyperCon and Surf Bio bring high-concentration tech enabling up to ~500 mg/ml biologics, promising smaller dose volumes.
• Financial guidance lift: Halozyme raised guidance, forecasting royalty revenues to hit $1 billion in 2026 and adjusted EBITDA above $1.125 billion.
• Patient convenience focus: Small-volume autoinjectors and concentration tech aim to let some therapies move from clinic infusions to at-home injections.

Directors elected and governance items cleared , what that signals

About 104.1 million shares were represented at the meeting, enough for a quorum, and shareholders elected Bernadette Connaughton and Matthew Posard as Class I directors. They also approved the advisory vote on executive pay and ratified Ernst & Young as Halozyme’s auditor. It’s routine corporate housekeeping, but it matters , clean governance gives management licence to push strategy without prolonged proxy fights. For investors it’s a reassuring tick in the box: leadership and oversight are aligned as the company pivots from platform growth to monetisation.

ENHANZE keeps being the business engine

Torley framed 2025 as a strong execution year, pointing to ENHANZE’s role in converting long IV infusions into rapid subcutaneous injections. The company now lists 10 globally approved ENHANZE-enabled products and sealed three new deals during 2025. That steady licensing cadence is central to Halozyme’s model: partner and enable, then collect royalties, so continued deal flow is the clearest sign the platform still resonates with pharma partners. If you’re watching Halozyme, look at future licensing announcements and launch timing for ENHANZE-enabled drugs as the key revenue catalysts.

Why HyperCon and Surf Bio matter for patients , and margins

The acquisitions of HyperCon and Surf Bio are about concentration, plain and simple: enabling biologics to be formulated at much higher concentrations , Torley talked about up to roughly 500 mg/ml. That can shrink dose volumes to a couple of millilitres, which opens the door to everyday auto-injectors and home administration. For patients, that’s convenience and fewer clinic visits; for Halozyme and partners, it’s a way to extend the ENHANZE story into new product formats and potentially higher-margin licensing. If you have a biologic that’s bulky today, these techs could change its route of delivery , and its commercial profile.

Autoinjectors, new deals and the evolving business model

Halozyme isn’t just licensing enzymes. The company is progressing autoinjector work, with one licensing and supply agreement and two development deals announced for small- and high-volume devices. Torley described the company’s economics as licensing-based, aimed at strong margins and free cash flow. Practically, that means Halozyme wants partners to carry development and commercial risk while it collects royalties and device income. For would-be partners and investors, the combination of concentrated formulations plus auto-injector capability is the kind of integrated offering big pharma finds attractive.

Guidance, buybacks and the litigation timeline , what investors heard

Torley raised the bar for 2026, saying royalty revenue should reach $1 billion , a year earlier than previously expected , and adjusted EBITDA should top $1.125 billion. She also reminded shareholders the company has returned nearly $2 billion through repurchases over the past five years and still has buyback capacity. On litigation, Halozyme expects a scheduling order in the Merck infringement case in June, and Torley warned trials can stretch for years unless a license is sought. That’s a sensible caveat: litigation risk remains, but the near-term story is stronger royalties and cash generation.

It's a small strategic shift with big implications for convenience, partnerships and royalties , worth keeping on your watchlist.

Source Reference Map

Story idea inspired by: ^[1]

Sources by paragraph:

• Paragraph 1: ^[2], ^[4]
• Paragraph 2: ^[2], ^[4]
• Paragraph 3: ^[2], ^[7]
• Paragraph 4: ^[2], ^[3]
• Paragraph 5: ^[2], ^[5]